Editing Brigham and Women's Hospital (section)

== What Clinical Trials Can Patients Access? ==

The IMP maintains an active clinical research program, building on Dr. Sugarbaker's legacy of advancing mesothelioma treatment through rigorous investigation.<ref>[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma Treatment], Mesothelioma.net</ref>

'''Current and Recent Trials'''

'''MAGIC AKI Trial:'''
Studying magnesium for the prevention of hyperthermic intraoperative chemotherapy-associated acute kidney injury in mesothelioma patients undergoing cytoreductive surgery.

'''Keytruda + Defactinib Combination:'''
Evaluating pembrolizumab (Keytruda) combined with defactinib prior to surgical resection, exploring whether immunotherapy before surgery can improve outcomes.

'''Prognostic Biomarker Study:'''
Investigating pleural mesothelioma prognostic biomarkers from prospectively collected pleural biopsies to better predict disease behavior.

'''Four-Gene Ratio Test Development:'''
Research into molecular testing that may help determine prognosis and guide treatment decisions.

'''Genomic Research Initiative'''

The IMP maintains a comprehensive genomic project that catalogs and shares mutations associated with mesothelioma, contributing to the broader scientific understanding of the disease and informing targeted therapy development.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✓ Research Partnerships:''' The IMP collaborates with Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston VA Health Care System, and Harvard School of Public Health, creating one of the most robust mesothelioma research networks in the world.
|}